摘要
目的观察生物微球联合碘油经肝动脉栓塞化疗(TACE)治疗不能手术切除的原发性肝癌患者的临床疗效。方法选择本院2010年1月至2012年12月40例行选择性肝动脉栓塞化疗时使用生物微球联合碘油栓塞化疗的原发性肝癌患者和42例行选择性肝动脉栓塞时使用碘油栓塞化疗的患者,每例行栓塞术4次以上,于首次术后1、3、6、12和24 m随访生存患者肝功能、甲胎蛋白、腹部增强CT等变化,比较治疗后病灶缩小程度,观察肿瘤部分缓解率及患者生存率。结果在首次术后3个月时,微球联合组肿瘤缓解率为(57.44%),明显高于TACE组[(45.23%),P<0.05],6个月时微球联合组AFP为(296.7±96.3)ng/ml,明显低于TACE组[(346.9±118.3)ng/ml,P<0.05],12个月时微球联合组肿瘤直径为(3.36±1.37)cm,明显低于TACE组[(4.98±1.87)cm,P<0.05],24个月时微球联合组生存率为(15.0%),明显高于TACE组[(2.3%),P<0.05]。结论生物微球联合碘油栓塞化疗治疗患者病灶缩小程度、AFP下降水平、肿瘤部分缓解率及患者生存率明显高于单纯碘油栓塞化疗组,生物微球联合碘油栓塞化疗治疗中晚期原发性肝癌疗效确切,临床疗效优于单纯栓塞化疗,且安全可行。
Objective To observe the clinical efficacy of selective transcatheter chemoembolization （TACE） with biologic microsphere and lipiodol in the treatment of patients with primary liver cancer （PLC）. Methods 82 patients with PLC in Daping hospital from January 2010 to December 2012 were included in this study and were divided into two groups. 42 patients received selective transcatheter chemoembolization with lipiodol,and 40 re- ceived selective transcatheter chemoembolization with both biologic microsphere and lipiodol. Each patient got chemoembolization at least four times. The follow-up assessment was conducted 1 month later as well as 3 months,6 months, 1 year and 2 years later after the first treatment to follow-up the decreased volume and number of tumor masses,serum AFP levels,the remission rates and survival. Results The remission rate of 57.44% in pa- tients treated with both biologic microsphere and lipiodol was obviously higher than that treated with lipiodol （TACE）（5.23%,P〈0.05） 3 months after the first operation. The serum level of AFP in the combined group got much lower （296.7±96.3）ng/ml than in the TACE group [（346.9±l18.3）ng/ml,P〈0.05] 6 months later. We found that the diameters of tumors were much smaller （3.36±1.37） cm in the combined group than in the TACE group [（4.98±l.87）cm,P〈0.05] 12 months later. And the survival rate in the combined group was much higher（15.0%） than that in the TACE group[（2.3%）,P〈0.05] 24 months later. Conclusions Compared with patients treated with chemoembolization and lipiodol,patients receiving chemoembolization with both biologic microsphere and lipiodol get increased remission of tumor masses,as well as decreased serum AFP levels. Selective transcatheter chemoem- bolization with biologic microsphere and lipiodol is effective and safe in treatment of advanced liver cancer.
出处
《实用肝脏病杂志》
CAS
2015年第3期245-248,共4页
Journal of Practical Hepatology
关键词
原发性肝癌
生物微球
选择性肝动脉栓塞化疗
疗效
Hepatoma
Biologic microsphere
Lipiodol
Selective transcatheter chemoembolization
Efficacy
